Sea buckthorn bioactive metabolites and their pharmacological potential in digestive diseases
Abstract
Sea buckthorn is a botanical drug with a long history of medicinal use in treating digestive diseases. It is considered "a food with medicinal and edible homology", meaning it has various application scenarios. Sea buckthorn is known to have numerous bioactivities, such as anti-inflammatory, flora-regulating, immunoregulating, intestinal protective, and anticancer properties, as a potential natural therapy for digestive diseases. In both in vitro and in vivo experiments, ranging from cell lines to animal models and human patients, sea buckthorn has shown beneficial effects on symptoms associated with digestive disease. This study reviews the main bioactive metabolites of sea buckthorn and discusses their pharmacological effects and mechanisms in treating digestive diseases. In particular, we highlight bioactive metabolites isolated from sea buckthorn, their effects on inflammation, cancer, anti-Helicobacter pylori, radiation, and gut microbiota, and their molecular mechanisms of action in clinical applications. This article provides insight into the benefits of sea buckthorn, encouraging academic research in this area and the expansion of sea buckthorn-based applications for digestive diseases.
How strong is the evidence?
Evidence Hub reads this as a review, done in animal and cell cultures (in vitro), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.